{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:17:33Z","timestamp":1776878253217,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400733"],"award-info":[{"award-number":["82400733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370635"],"award-info":[{"award-number":["82370635"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2023JJ40927"],"award-info":[{"award-number":["2023JJ40927"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2023JJ30892"],"award-info":[{"award-number":["2023JJ30892"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mother-to-child transmission (MTCT) is the primary cause of hepatitis B virus (HBV) infection. Antiviral therapy is crucial to reduce MTCT for pregnant women with high viremia. Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are the first-line antiviral drugs for hepatitis B. This study aimed to evaluate the effectiveness and safety of TAF and TDF in preventing HBV MTCT among treatment-na\u00efve mothers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 290 pregnant women with HBsAg positive for &gt;\u20096 months, and HBV DNA\u2009\u2265\u20092\u2009\u00d7\u200910^5 IU\/ml or HBeAg positive were enrolled. Mothers received either TDF or TAF therapy and newborns received hepatitis B immunoglobulin and recombinant yeast hepatitis B vaccine. MTCT was evaluated during a one-year follow-up period after birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      290 pregnant women (185 with TDF therapy and 105 with TAF therapy) and 296 newborns (190 in TDF group and 106 in TAF group) were included. Both TDF and TAF effectively deceased HBV DNA levels with no significant difference, and the MTCT rates in TDF group and TAF group were similarly low (1.08% vs. 0.95%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Moreover, no congenital malformations or growth and developmental abnormalities in newborns were observed in either group. However, serum creatinine was significantly higher and eGFR decreased significantly when treated by TDF, whereas TAF showed no significant renal effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both TAF and TDF are effective in preventing HBV MTCT, with comparable MTCT rates. However, TAF demonstrated superior renal safety, making it a preferable option for preventing HBV MTCT in treatment-na\u00efve mothers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-026-03074-9","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:08:19Z","timestamp":1770012499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Na\u00efve mothers: An Observational Study"],"prefix":"10.1186","volume":"23","author":[{"given":"Xueyao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zebing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"10381","key":"3074_CR1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B [J]. Lancet (London, England). 2023;401(10381):1039\u201352.","journal-title":"Lancet (London, England)"},{"key":"3074_CR2","unstructured":"WHO, Hepatitis. B [J]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b, 18 July 2023."},{"issue":"10","key":"3074_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026748","volume":"6","author":"H Zou","year":"2011","unstructured":"Zou H, Chen Y, Duan Z, et al. Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers [J]. PLoS One. 2011;6(10):e26748.","journal-title":"PLoS One"},{"issue":"2","key":"3074_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jhep.2013.04.019","volume":"59","author":"KW Cheung","year":"2013","unstructured":"Cheung KW, Seto MT, Lee CP. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention [J]. Journal of Hepatology. 2013;59(2):400.","journal-title":"Journal of Hepatology"},{"issue":"1","key":"3074_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/AOG.0b013e3181e45951","volume":"116","author":"Z Shi","year":"2010","unstructured":"Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis [J]. Obstetrics and Gynecology. 2010;116(1):147\u201359.","journal-title":"Obstetrics and gynecology"},{"key":"3074_CR6","doi-asserted-by":"crossref","unstructured":"Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice [J]. Hepatology (Baltimore, Md)2014.","DOI":"10.1002\/hep.27034"},{"issue":"1","key":"3074_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","volume":"21","author":"AL Funk","year":"2021","unstructured":"Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis [J]. The Lancet Infect Diseases. 2021;21(1):70\u201384.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"3074_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.29187","volume":"66","author":"YS Lim","year":"2017","unstructured":"Lim YS, Lee YS, Gwak GY, et al. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial [J]. Hepatology (Baltimore, Md). 2017;66(3):772\u201383.","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"3074_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12072-019-09943-6","volume":"13","author":"X Liang","year":"2019","unstructured":"Liang X, Gao Z, Xie Q, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results [J]. Hepatol Int. 2019;13(3):260\u20139.","journal-title":"Hepatol Int"},{"issue":"11","key":"3074_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","volume":"35","author":"N Gara","year":"2012","unstructured":"Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B [J]. Aliment Pharmacol Ther. 2012;35(11):1317\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3074_CR11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/cid\/civ437","volume":"61","author":"GK Siberry","year":"2015","unstructured":"Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy [J]. Clin Infect Dis. 2015;61(6):996\u20131003.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3074_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1939","volume":"73","author":"QL Zeng","year":"2021","unstructured":"Zeng QL, Yu ZJ, Ji F, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study [J]. Clin Infect Dis. 2021;73(9):e3324-e32.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3074_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/MCG.0000000000001785","volume":"57","author":"L Zhu","year":"2023","unstructured":"Zhu L, Park J, Deng Y, et al. The use of Tenofovir disoproxil fumarate and Tenofovir Alafenamide for preventing vertical transmission of hepatitis B [J]. J Clin Gastroenterol. 2023;57(2):127\u201338.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"3074_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/apt.17040","volume":"56","author":"T Kayes","year":"2022","unstructured":"Kayes T, Crane H, Symonds A, et al. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection [J]. Aliment Pharmacol Ther. 2022;56(3):510\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"3074_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/v14020434","author":"RN Chien","year":"2022","unstructured":"Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14020434.","journal-title":"Viruses"},{"issue":"4","key":"3074_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection [J]. J Hepatol. 2018;68(4):672\u201381.","journal-title":"J Hepatol"},{"issue":"9","key":"3074_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/INF.0000000000000315","volume":"33","author":"X Lin","year":"2014","unstructured":"Lin X, Guo Y, Zhou A, et al. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: a hospital-based study and a meta-analysis [J]. Pediatr Infect Dis J. 2014;33(9):897\u2013903.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"3074_CR18","first-page":"399","volume":"32","author":"D Yang","year":"2024","unstructured":"Yang D, Qiuju S, Xiaoguang D. Strategies for hepatitis B virus-infected patients in the immune-tolerant phase: complete therapy at the last mile [J]. Chin J Hepatol. 2024;32(5):399\u2013401.","journal-title":"Chin J Hepatol"},{"key":"3074_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bpobgyn.2020.02.014","volume":"68","author":"KW Cheung","year":"2020","unstructured":"Cheung KW, Lao TT. Hepatitis B - vertical transmission and the prevention of mother-to-child transmission [J]. Best Pract Res Clin Obstet Gynaecol. 2020;68:78\u201388.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"3074_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12072-021-10235-1","volume":"15","author":"B Li","year":"2021","unstructured":"Li B, Liu Z, Liu X, et al. Efficacy and safety of Tenofovir disoproxil fumarate and Tenofovir Alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load [J]. Hep Intl. 2021;15(5):1103\u20138.","journal-title":"Hep Intl"},{"issue":"8","key":"3074_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/apt.16043","volume":"52","author":"Y Ding","year":"2020","unstructured":"Ding Y, Cao L, Zhu L, et al. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study [J]. Aliment Pharmacol Ther. 2020;52(8):1377\u201386.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3074_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jhep.2013.02.015","volume":"59","author":"WH Wen","year":"2013","unstructured":"Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention [J]. J Hepatol. 2013;59(1):24\u201330.","journal-title":"J Hepatol"},{"issue":"8","key":"3074_CR23","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/liv.15249","volume":"42","author":"G Samadi Kochaksaraei","year":"2022","unstructured":"Samadi Kochaksaraei G, Shaheen AA, Seow CH, et al. Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission-a review of maternal and infant outcomes. Liver international : official journal of the International Association for the Study of the Liver,2022;42(8):1712\u20131730.","journal-title":"Liver Int"},{"issue":"4","key":"3074_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","volume":"65","author":"A Boyd","year":"2016","unstructured":"Boyd A, Lacombe K, Lavocat F, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients [J]. J Hepatol. 2016;65(4):683\u2013 691.","journal-title":"J Hepatol"},{"issue":"1","key":"3074_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr., et al. Antiviral therapy for chronic hepatitis B viral infection in adults. A systematic review and meta-analysis [J]. Hepatology (Baltimore, Md.). 2016;63(1):284\u2013306.","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"11","key":"3074_CR26","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1007\/s10620-014-3230-3","volume":"59","author":"PJ Tsai","year":"2014","unstructured":"Tsai PJ, Chang A, Yamada S, et al. Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women [J]. Dig Dis Sci. 2014;59(11):2797\u2013803.","journal-title":"Dig Dis Sci"},{"key":"3074_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.intimp.2016.11.022","volume":"42","author":"Y Han","year":"2017","unstructured":"Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis [J]. Int Immunopharmacol. 2017;42:168\u201375.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3074_CR28","first-page":"525","volume":"28","author":"G Di Perri","year":"2020","unstructured":"Di Perri G. Tenofovir alafenamide revisited [J]. Le Infez Med. 2020;28(4):525\u201333.","journal-title":"Le Infez Med"},{"key":"3074_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.fct.2016.11.029","volume":"99","author":"H Ramamoorthy","year":"2017","unstructured":"Ramamoorthy H, Abraham P, Isaac B, et al. Role for NF-\u03baB inflammatory signalling pathway in tenofovir disoproxil fumarate (TDF) induced renal damage in rats [J]. Food Chem Toxicol. 2017;99:103\u201318.","journal-title":"Food Chem Toxicol"},{"issue":"24","key":"3074_CR30","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"CQ Pan","year":"2016","unstructured":"Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load [J]. N Engl J Med. 2016;374(24):2324\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"3074_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/apt.15064","volume":"49","author":"M Wang","year":"2019","unstructured":"Wang M, Bian Q, Zhu Y, et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load [J]. Alimentary pharmacology & therapeutics. 2019;49(2):211\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3074_CR32","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/liv.15873","volume":"44","author":"HL Chen","year":"2024","unstructured":"Chen HL, Lee CN, Chang CH, et al. Tenofovir Alafenamide or Tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: maternal ALT trajectory and infant outcomes[J]. Liver Int. 2024;44(6):1422\u201334.","journal-title":"Liver Int"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03074-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:03:54Z","timestamp":1772582634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3074"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03074-9","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in compliance with the Declaration of Helsinki and was approved by Xiangya Hospital Ethics Committee, Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}